Immunotherapy of mycobacterial infections

Seminars in Respiratory Infections

Volumn 16, Issue 1, 2001, Pages 47-59

  Holland, Steven M ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MSC 1886 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12;

DRUG EFFECT; GENETIC SUSCEPTIBILITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION CONTROL; MACROPHAGE ACTIVATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 0035066435     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2001.22728     Document Type: Review

References (97)

1. Interferon gamma and interleukin-12 pathway defects and human disease
2. Nontuberculous mycobacterial pulmonary disease
3. Infection with Mycobacterium avium complex in patients without predisposing conditions
4. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex
5. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome
6. New developments in the treatment of nontuberculous mycobacterial (NTM) disease
7. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis
8. Cellular responses to interferon-γ
9. Interferon-gamma in the management of infectious diseases
10. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway
11. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages
12. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice
13. Transient loss of resistance to pulmonary tuberculosis in p47phox -/- mice
14. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria
15. Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages
16. Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex
17. Disseminated tuberculosis in interferon gamma gene-disrupted mice
18. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
19. Mice that lack the interferon-gamma receptor have profoundly altered responsess to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide
20. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages
21. Defects in cell-mediated immunity affect chronic, but not innate, resistance of mice to Mycobacterium avium infection
22. 2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-γ
23. Familial disseminated atypical mycobacterial infection in childhood: A human mycobacterial susceptibility gene?
24. Defective antigen processing associated with familial disseminated mycobacteriosis
25. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection
26. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection
27. Detection of intracellular phosphorylated STAT-1 by flow cytometry
28. Abnormal regulation of interferon-γ, interleukin-12, and tumor necrosis factor-α in human interferon-γ receptor 1 deficiency
29. Viral infections in interferon-gamma receptor deficiency
30. Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection
31. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis
32. A human IFNGRI small deletion hotspot associated with dominant susceptibility to mycobacterial infection
33. Inhibition of cellular responsiveness to interferon gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor
34. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection
35. A novel IFNGR2 mutation associated with disseminated M. abscessus infection in a Qatari infant
36. Partial Interferon-gamma receptor signaling chain deficiency in a patient with Bacille Calmette-Guerin and Mycobacterium abscessus infection
37. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: Role of phagocytosis
38. Interleukin- 12: Basic principles and clinical applications
39. Early Interleukin 12 production by macrophages in response to Mycobacterial infection depends on interferon γ and tumor necrosis factor α
40. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium
41. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report
42. Defective monocyte costimulation for IFN-γ production in familial disseminated Mycobacterium avium complex infection: Abnormal IL-12 regulation
43. IL-12-independent costimulation pathways for interferon-gamma production in familial disseminated Mycobacterium avium complex infection
44. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection
45. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients
46. Isolated cutaneous response to granulocyte-monocyte colony stimulating factor in fatal idiopathic disseminated bacillus Calmette-Guerin infection
47. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency
48. The Garrod lecture: Understanding the chemotherapy of tuberculosis-current problems
49. Principles of therapy of tuberculosis in the modern era
50. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis
51. A multi-institutional outbreak of highly drag-resistant tuberculosis
52. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
53. Tuberculosis in patients infected with human immunodeficiency virus: Perspective on the past decade
54. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
55. Forsetzung der mittheilung uber ein heilmittel gegen tuberkulose
56. Tuberculin immunization in the treatment of pulmonary tuberculosis
57. Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: Role of LFA-I
58. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages
59. Treatment of experimental disseminated Mycobacterium avium complex in mice with recombinant IL-2 and tumor necrosis factor
60. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2
61. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy
62. Leprosy and cell-mediated immunity
63. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy
64. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis
65. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients
66. Local and systemic effects of intradermal recombinant interferon-γ in patient with lepromatous leprosy
67. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients
68. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients
69. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis
70. Interferon gamma and Mycobacterium avium-intracellulare infection
71. Interferon gamma treatment for Mycobacterium avium-intracellulare complex bacillemia in patients with AIDS
72. Organ specific cytokine therapy: Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to the human lung
73. Aerosolized interferon gamma for Mycobacterium avium-complex lung disease
74. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
75. Use of adjunctive treatment with interferon-γ in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain
76. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol
77. Stimulation with cytokines enhances penetration of azithromycin into human macrophages
78. Immuno-chemotherapy for intracellular Leishmania donovani infection: Gamma interferon plus pentavalent antimony
79. Effect of treatment with interferon-γ alone in visceral leishmaniasis
80. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
81. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
82. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis
83. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: Longterm follow-up
84. Interleukin-12 (IL-12) treatment in interferon gamma refractory pulmonary M. abscessus infection: Clinical response of immunologic reconstitution
85. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-gamma production
86. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex
87. Interferon decreases the growth inhibition of Mycobacterium avium-intracellulare complex by fresh human monocytes but not by culture derived macrophages
88. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model
89. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor
90. Corticosteroids in the treatment of tuberculous pleurisy: A double-blind, placebo-controlled, randomized study
91. Low dose dexamethasone as adjunctive therapy for disseminated Mycobacterium avium complex infections in AIDS patients
92. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
93. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
94. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis
95. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: A randomized, controlled trial
96. Effect of rhulFN-gamma treatment in multibacillary leprosy patients